Mobilization and harvesting of HSC from PBSC is an essential part of autologous transplantation, but the optimal strategy for it remains unclear. Usually, HSC mobilization includes administration of G-CSF, alone or in combination with chemotherapy, 3 to harvest a minimum of 2.0 Â 10 6 CD34 þ cells/kg for rapid engraftment after a myeloablative conditioning regimen. Nevertheless, it is estimated that 2-40% of patients fail to achieve the minimal cellular dose for transplant. 4 This retrospective study has the purpose to unveil the characteristics of HSC mobilization in patients with T1DM. We reviewed the records of 25 patients with T1DM enrolled at our institution. All the patients were within 6 weeks from diagnosis, when they were submitted to mobilization and harvesting of HSC. Our hypothesis is that these patients are 'good mobilizers' as they were not previously exposed to drugs toxic to HSC or BM stroma. CD34 þ cells were mobilized with CY (2 g/m 2 ) associated with G-CSF (median 9.4 mg/kg/day; range 4.9-12.5 mg/kg/ day), initiated the day after the CY administration and continued daily until cell collection, and harvested through peripheral access from all the patients. Harvesting was initiated when the CD34 þ cell count reached a minimum of 10/mL in peripheral blood. Aphereses were performed using the continuous-flow blood cell separator COBE Spectra (Caridian BCT, Lakewood, CO, USA). The results were shown as median and range. To compare eventual differences Mann-Whitney test (significance set at Po0.05) was used. This study was approved by the local and National Research Ethics Committee.
Median age of the patients was 17 years (13-31). Eighteen (72%) of them were male (Table 1) . Median CD34 þ cell concentration in peripheral blood was 80.9 (36.5-167.6)/mL on the day of apheresis, however, in males and females the CD34 þ cell concentrations were /kg (5.2-9.60) for female patients (P ¼ 0.0566), despite the similar total blood volumes processed (3 in female vs 2.5 in male patients; P ¼ 0.1573). The processed total blood volume was 2.6mL (2.2-3.4) in 215 (152-280) minutes. CD34
þ cell harvest was performed on day 8 (7-9) ( Table 1 ). A total of seven patients (28%) presented adverse reactions that could be attributed to the mobilization regimen, such as headache, myalgia and malaise. One patient had febrile neutropenia. Eight patients (32%) had adverse reactions related to the apheresis procedure, especially due to citrate toxicity (Table 2 ). In two patients insulin could be discontinued during the conditioning regimen. No patients died before engraftment. Neutrophil engraftment occurred on day 11 (9-13) in both female and male patients.
HSC mobilization characteristics in patients with CAID are relatively well established. 5, 6 The same cannot be asserted for patients with T1DM. Herein, we found that all 25 patients with T1DM had an efficient CD34 þ cell mobilization with CY and G-CSF, demonstrated by the high concentration and the early peak of CD34 þ cells in the peripheral blood. These phenomena are commonly observed in 'good mobilizers', and suggest that HSC and the BM microenvironment in T1DM patients are not damaged. According to Stiff, 7 patients can be stratified into three categories regarding mobilization efficiency: (A) easily mobilizable (45 Â 10 6 /kg), (B) difficult to mobilize (1-5 Â 10 6 /kg) and (C) non-mobilizable (o1 Â 10 6 /kg) after repeated apheresis attempts. The patients in this study can be considered easily mobilizable as all of them had a CD34 þ cell collection superior to 5 Â 10 6 /kg with a single apheresis. Mobilization characteristics are influenced by the strategies employed, patients' diagnoses and type of previous treatment. 8 Approximately 10% of patients with CAID failed to mobilize HSC. 6 Patients with systemic lupus erythematosus achieved the lowest CD34 þ number in peripheral blood and the lowest cell yield, whereas patients with multiple sclerosis or scleroderma achieved the highest. Furthermore, Statkute et al, 5 had to perform a mean of 1.8 apheresis sessions per patient with CAID (2.5 for those with lupus). Overall, patients with T1DM needed approximately half the apheresis sessions relative to patients with other autoimmune diseases, possibly because T1DM patients were 'healthier' than patients with CAID. The good mobilization observed resulted in an adequate neutrophil engraftment (on day 11).
Only one patient presented a significant complication (febrile neutropenia) during mobilization. Approximately 30% (8/25) of the patients had a mild adverse effects that could be attributed to mobilization regimen or citrate toxicity (bone pain and paresthesia), which is lower than expected. 9 Possible explanations for this finding could be the younger age of our patients, and the fact that B70% of them were of male gender, supposedly less prone to present some side effects 10 related to mobilization with G-CSF.
In conclusion, patients with T1DM mobilize HSC efficiently with CY and G-CSF. Toxicity associated with mobilization and cell harvest occurred in a minority of patients. These findings suggest that patients with T1DM could be safely submitted to HSC mobilization and harvest.
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